AlphAIAlphAI — Financial news for AI agents
stocktitan.net

Artivion will release results after market close Nov. 5, then host a 4:30 p.m. ET call.

Artivion, Inc. will release its Q3 2026 financial results after market close on Nov. 5, followed by a teleconference at 4:30 p.m. ET. The company's products include aortic stent grafts, surgical sealants, and heart valves. A replay and webcast will be available post-event. Artivion operates in over 100 countries. The earnings press release will be on the company's website.

Original reporting
stocktitan.net
Published Oct 22, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$AORT
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

Low
01

Why it matters

The announcement sets the timeline for investors to prepare for the earnings release; no immediate market move is expected.

02

Market read

Informational release schedule; low immediate trading relevance.

03

What to watch

Potential impact of upcoming results on related aortic device competitors.

Relevance 5/10Novelty 4/10Timing: after-market close Nov. 5

Background

Artivion is a medical device company focused on aortic disease treatments. The article is a standard earnings release announcement.

Market effects

Sector

None disclosed; the announcement does not affect the broader medical device sector.

Regional

Limited to investors tracking Artivion.

Global

Minimal.

Counterpoint

What could challenge this read

Some traders may view the lack of detail as a sign to stay out until results are released.

Key entities

  • company
    Artivion, Inc.

    Medical device manufacturer announcing its Q3 2026 earnings release.

Read at source← All news

Related articles

$AORTMed

Artivion: Q3 Earnings Snapshot

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

finance.yahoo.com
$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

SEC EDGAR 8-K
$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.

prnewswire.com
$AORTHigh

Why is Artivion stock rallying today?

Artivion (AORT) stock rose 4.7% after Jefferies initiated coverage with a Buy rating and $31 price target, citing near-term product catalysts and growth potential. The firm expects 39% upside from the prior close, highlighting product launches and margin accretion. Artivion's Q3 2026 earnings report is due soon, adding to near-term interest.

investing.com
$AORTMed

Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’

Artivion Inc (NYSE:AORT) shares rose 4.2% after Jefferies initiated coverage with a Buy rating and $31 price target. The firm cited the company's expanding product pipeline, expected double-digit revenue growth, and expanding profit margins. Jefferies forecasts $547M and $617M in revenue for 2027 and 2028, respectively, above consensus. The stock is seen as undervalued relative to peers, offering an attractive entry point ahead of commercial catalysts.

investing.com